Gland Pharma

Gland Pharma reported its June-quarter performance today, Monday, after market hours, with consolidated net profit rising 47% YoY to ₹317 crore, compared with ₹215.5 crore in Q1 FY26. However, on a sequential basis, net profit declined 14% from ₹366.7 crore in Q4 FY26. Revenue from operations increased 20% YoY to ₹1,800 crore, from ₹1,505 crore in the year-ago quarter and was up 3% sequentially from ₹1,743 crore. Business-wise, the CDMO business remained a key growth driver, with revenue rising 20% YoY to ₹891.5 crore, while also registering an 11% sequential increase from ₹806 crore, supported by recent product launches